Compare NVAX & LMAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NVAX | LMAT |
|---|---|---|
| Founded | 1987 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 2.1B |
| IPO Year | 1996 | 2006 |
| Metric | NVAX | LMAT |
|---|---|---|
| Price | $9.96 | $78.96 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 9 | 5 |
| Target Price | $11.33 | ★ $105.80 |
| AVG Volume (30 Days) | ★ 5.3M | 240.6K |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 0.93% |
| EPS Growth | ★ 309.76 | 30.57 |
| EPS | N/A | ★ 1.42 |
| Revenue | ★ $1,123,479,000.00 | $249,602,000.00 |
| Revenue This Year | N/A | $14.21 |
| Revenue Next Year | N/A | $8.88 |
| P/E Ratio | ★ N/A | $55.96 |
| Revenue Growth | ★ 64.69 | 13.53 |
| 52 Week Low | $6.20 | $78.27 |
| 52 Week High | $11.85 | $118.01 |
| Indicator | NVAX | LMAT |
|---|---|---|
| Relative Strength Index (RSI) | 60.72 | 37.39 |
| Support Level | $9.12 | $78.65 |
| Resistance Level | $10.36 | $83.71 |
| Average True Range (ATR) | 0.62 | 1.82 |
| MACD | -0.03 | 0.46 |
| Stochastic Oscillator | 54.53 | 15.69 |
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
LeMaitre Vascular Inc is a provider of medical devices and human tissue cryopreservation services mainly used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser extent, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Its diversified portfolio consists of branded products used in arteries and veins that are well known to vascular surgeons. It operates across the Americas, Europe, the Middle East and Africa, and Asia Pacific, with the majority of its revenue generated from the Americas.